{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"94.873","value":"-42.97"},{"groupId":"OG001","spread":"140.589","value":"-46.84"},{"groupId":"OG002","spread":"265.694","value":"-70.39"},{"groupId":"OG003","spread":"58.443","value":"-33.80"},{"groupId":"OG004","spread":"54.228","value":"-18.67"}]}],"title":"Wk 8 (n=127,112,85,6,24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"158.951","value":"-68.23"},{"groupId":"OG001","spread":"144.256","value":"-56.76"},{"groupId":"OG002","spread":"219.466","value":"-72.96"},{"groupId":"OG003","spread":"149.881","value":"-70.33"},{"groupId":"OG004","spread":"89.763","value":"-64.32"}]}],"title":"Wk 24 (n=117,107,82,4,24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"151.086","value":"-72.99"},{"groupId":"OG001","spread":"223.577","value":"-82.51"},{"groupId":"OG002","spread":"307.981","value":"-127.21"},{"groupId":"OG003","spread":"42.881","value":"-28.98"},{"groupId":"OG004","spread":"167.012","value":"-81.57"}]}],"title":"Wk 48 (n=116,102,87,4,22)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"112"},{"groupId":"OG002","value":"87"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"24"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received rituximab, 0.5 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG000","title":"Rituximab Low Dose + Methotrexate"},{"description":"Participants received rituximab, 0.5 g, IV, on Days 1 and 15 and 1.0 g, IV, on Days 168 and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG001","title":"Rituximab Escalated Dose + Methotrexate"},{"description":"Participants received rituximab, 1.0 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG002","title":"Rituximab High Dose + Methotrexate"},{"description":"Participants received rituximab, 1.0 g, IV, on Days 1 and 15, and a placebo, IV, on Days 168 and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose. This treatment group was not part of the planned analysis and was not analyzed for all outcomes measures since they did not receive the planned treatment.","id":"OG003","title":"Rituximab/Placebo + Methotrexate"},{"description":"Participants received rituximab, 1.0 g, IV, on Days 1 and 15 and 0.5 g, IV, on Days 168 and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose. This treatment group was not part of the planned analysis and was not analyzed for all outcomes measures since they did not receive the planned treatment.","id":"OG004","title":"Rituximab Decreased Dose + Methotrexate"}],"paramType":"MEAN","populationDescription":"SAP, n = number of participants assessed for the given parameter at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Weeks 8, 24, and 48","title":"Change From BL in Anti-CCP Antibody Titers in U/mL","type":"SECONDARY","unitOfMeasure":"U/mL"}